Actinium Pharmaceuticals Inc (ATNM)

1.35
0.35 21.00
AMEX : Health Care
Prev Close 1.70
Open 1.36
Day Low/High 1.31 / 1.40
52 Wk Low/High 1.52 / 3.50
Volume 2.33M
Avg Volume 316.10K
Exchange AMEX
Shares Outstanding 47.72M
Market Cap 81.12M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Actinium Pharmaceuticals To Sponsor And Participate In Be The Match® Walk+Run To Raise Awareness For Bone Marrow Transplant

Actinium Pharmaceuticals To Sponsor And Participate In Be The Match® Walk+Run To Raise Awareness For Bone Marrow Transplant

Awareness and Fundraising Event to be Held on Saturday, October 1, 2016

Actinium Pharmaceuticals Selects Vector Oncology As Its Clinical Research Organization For Actimab-A Phase 2 Trial

Actinium Pharmaceuticals Selects Vector Oncology As Its Clinical Research Organization For Actimab-A Phase 2 Trial

CRO Selection Represents Key Milestone in Phase 2 Trial Initiation Process

These 5 Stocks Are Breaking Out

These 5 Stocks Are Breaking Out

Here's how to trade five stocks that are ready to break out and trade higher from current levels.

First Week of March 18th Options Trading For Actinium Pharmaceuticals (ATNM)

First Week of March 18th Options Trading For Actinium Pharmaceuticals (ATNM)

Investors in Actinium Pharmaceuticals, Inc. saw new options begin trading this week, for the March 18th expiration.

First Week Of September 18th Options Trading For Actinium Pharmaceuticals (ATNM)

First Week Of September 18th Options Trading For Actinium Pharmaceuticals (ATNM)

Investors in Actinium Pharmaceuticals, Inc. saw new options begin trading this week, for the September 18th expiration.

Interesting ATNM Put Options For February 2016

Interesting ATNM Put Options For February 2016

Investors in Actinium Pharmaceuticals, Inc. saw new options begin trading this week, for the February 2016 expiration.

Short Interest Increases 18% For ATNM

Short Interest Increases 18% For ATNM

The most recent short interest data has been released by the NASDAQ for the 05/15/2015 settlement date, which shows a 387,097 share increase in total short interest for Actinium Pharmaceuticals, Inc. , to 2,526,804, an increase of 18.09% since 04/30/2015.

Interesting ATNM Put And Call Options For November 20th

Interesting ATNM Put And Call Options For November 20th

Investors in Actinium Pharmaceuticals, Inc. saw new options begin trading this week, for the November 20th expiration.

Actinium Announces Pricing Of Public Offering Of Common Stock And Warrants To Purchase Common Stock

Actinium Announces Pricing Of Public Offering Of Common Stock And Warrants To Purchase Common Stock

Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE MKT:ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the...

3 Biotech Stocks Under $10 in Breakout Territory

3 Biotech Stocks Under $10 in Breakout Territory

Keep these under-$10 biotech stocks on your breakout trading radar.

5 Breakout Stocks Under $10 Set to Soar Higher

5 Breakout Stocks Under $10 Set to Soar Higher

These stocks trading for less than $10 a share are within range of triggering breakout trades.

MD Anderson Department Chair Richard E. Champlin, M.D. Joins Actinium’s Iomab™-B Scientific Advisory Board

MD Anderson Department Chair Richard E. Champlin, M.D. Joins Actinium’s Iomab™-B Scientific Advisory Board

Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today ...

Actinium Files Orphan Drug Application For Use Of Actimab-A In The Treatment Of Newly Diagnosed Acute Myeloid Leukemia In Elderly Patients

Actinium Files Orphan Drug Application For Use Of Actimab-A In The Treatment Of Newly Diagnosed Acute Myeloid Leukemia In Elderly Patients

Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today ...

Actinium To Present At The Rodman & Renshaw Annual Global Investment Conference On September 10th

Actinium To Present At The Rodman & Renshaw Annual Global Investment Conference On September 10th

Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced...

Actinium To Present At The Canaccord Genuity 34th Annual Growth Conference On August 13th

Actinium To Present At The Canaccord Genuity 34th Annual Growth Conference On August 13th

Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced...

Actinium Pharmaceuticals Provides Mid-Year Update Directed At Existing And Future Shareholders

Actinium Pharmaceuticals Provides Mid-Year Update Directed At Existing And Future Shareholders

Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today provided...

Baylor Sammons Cancer Center Joins As Clinical Trial Site For Actinium’s Actimab-A Clinical Trial

Baylor Sammons Cancer Center Joins As Clinical Trial Site For Actinium’s Actimab-A Clinical Trial

Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today ...